HIV-associated neurocognitive disorder in HIV patients substantially reduces their quality of life. We previously showed that the HIV matrix protein, p17 could stimulate lymph-angiogenesis in vitro potentially contributing to lymphoma tumour growth and in addition is associated with vascular activation in neuro-degenerating brain tissue; here, therefore, we have investigated the detailed molecular mechanisms of this action. We performed in vitro cell culture, angiogenesis experiments, phospho-protein microarrays and Western blotting to identify cellular signalling induced by p17 within human brain endothelial cells (HbMEC), and inhibitor studies to block p17-induced vascular growth. We also characterised the effects of hippocampal CA1 injection of p17 on epidermal growth factor receptor-1 (EGFR1) expression linked to our murine model of dementia. p17 strongly induced angiogenesis of HbMEC (migration, tube formation and spheroid growth). p17 concomitantly increased phosphorylation of EGFR1 as well as down-stream intermediates ERK1/2, FAK, PLC-γ and PKC-β whilst an inhibitor peptide of EGFR, blocked cell signalling and angiogenesis. Finally, Mice that showed reduced cognitive function and behavioural deficiencies after p17 injection, demonstrated that p17 localised in cortical microvessels and also neurones many of which stained positive for p-EGFR1 by histology/IHC. This work provides strong support that p17 may be involved in initiating and/or perpetuating vascular tissue pathophysiology associated with comorbidity in HIV patients.

Access optionsAccess options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.


  1. 1.

    Goulet JL, Fultz SL, Rimland D, Adeel Butt, Cynthia Gibert, et al. Do patterns of comorbidity vary by HIV status, age, and HIV severity? Clin Infect Dis. 2007;45:1593–601.

  2. 2.

    Lorenc A, Banarsee R, Robinson N. Complementary therapy provision in a London community clinic for people living with HIV/AIDS: a case study. Complement Ther Clin Prac.. 2014;20:65–69.

  3. 3.

    Zigmond T. Mental health law across the UK. BJPsych Bull. 2017;41:305–7.

  4. 4.

    Caccuri F, Rueckert C, Giagulli C, Schulze K, Basta D, Zicari S, et al. HIV-1 matrix protein p17 promotes lymphangiogenesis and activates the endothelin-1/endothelin B receptor axis. ATVB.. 2014;34:846–56.

  5. 5.

    Zeinolabediny Y, Caccuri F, Colombo L, Morelli F, Romeo M, Rossi A, et al. HIV-1 matrix protein p17 misfolding forms toxic amyloidogenic assemblies that induce neurocognitive disorders. Sci Rep. 2017;7:10313.

  6. 6.

    Fiorentini S, Marini E, Caracciolo S, Caruso A. Functions of the HIV-1 matrix proteinp17. Microbiol-QJ Microbiol Sci.. 2006;29:1–10.

  7. 7.

    Giombini E, Dolcetti R, Caccuri F, Selleri M, Rozera G, Abbate I, et al. Detection of HIV-1 matrix protein p17 quasispecies variants in plasma of chronic HIV-1–infected patients by ultra-deep pyrosequencing. JAIDS.. 2014;66:332–9.

  8. 8.

    Caccuri F, Giagulli C, Bugatti A, Benetti Anna, Alessandri Giulio, Ribatti Domenico, et al. HIV-1 matrix protein p17 promotes angiogenesis via chemokine receptors CXCR1 and CXCR2. Proc Natl Acad Sci USA. 2012;109:14580–5.

  9. 9.

    Caccuri F, Giagulli C, Reichelt J, Martorelli D, Marsico S, Bugatti A, et al. Simian immunodeficiency virus and human immunodeficiency virus type 1 matrix proteins specify different capabilities to modulate B cell growth. J Virol. 2014;88:5706–17.

  10. 10.

    Popovic M, Tenner-Racz K, Pelser C, Stellbrink HJ, van Lunzen J, Lewis G, et al. Persistence of HIV-1 structural proteins and glycoproteins in lymph nodes of patients under highly active antiretroviral therapy. Proc Natl Acad Sci USA. 2005;102:14807–12.

  11. 11.

    Fiorentini S, Riboldi E, Facchetti F, Avolio Manuela, Fabbri Marco, Tosti Giorgio, et al. HIV-1 matrix protein p17 induces human plasmacytoid dendritic cells to acquire a migratory immature cell phenotype. Proc Natl Acad Sci USA. 2008;105:3867–72.

  12. 12.

    Fiorentini S, Giagulli C, Caccuri F, Magiera AK, Caruso A. HIV-1 matrix proteinp17: a candidate antigen for therapeutic vaccines against AIDS. Pharmacol Ther. 2010;128:433–44.

  13. 13.

    Tozzi V, Balestra P, Serraino D, Bellagamba R, Corpolongo A, Piselli P, et al. Neurocognitive impairment and survival in a cohort of HIV-infected patients treated with HAART. AIDS Res & Human Retrovir.. 2005;21:706–13.

  14. 14.

    Sevigny JJ, Albert SM, McDermott MP, Schifitto G, McArthur JC, Sacktor N, et al. An evaluation of neurocognitive status and markers of immune activation as predictors of time to death in advanced HIV infection. Arch Neurol. 2007;64:97–102.

  15. 15.

    Tozzi V, Balestra P, Bellagamba R, Corpolongo A, Salvatori MF, Visco-Comandini U, et al. Persistence of neuropsychologic deficits despite long-term highly active antiretroviral therapy in patients with HIV-related neurocognitive impairment: prevalence and risk factors. JAIDS.. 2007;45:174–82.

  16. 16.

    Brew BJ, Chan P. Update on HIV dementia and HIV-associated neurocognitive disorders. Curr Neurol Neurosci Rep. 2014;14:468.

  17. 17.

    Rempel H, Sun B, Calosing C, Abadjian Linda, Montoand Alexander, Pulliam Lynn. Monocyte activation in HIV/HCV coinfection correlates with cognitive impairment. PLoS ONE. 2013;8:e55776.

  18. 18.

    Crews L, Patrick C, Achim CL, Everall IanP, Masliah Eliezer. Molecular pathology of neuro-AIDS (CNS-HIV). Int J Mol Sci. 2009;10:1045–63.

  19. 19.

    Montoya JL, Iudicello J, Fazeli PL, Hong S, Potter M, Ellis RJ, et al. Elevated markers of vascular remodeling and arterial stiffness are associated with neurocognitive function in older HIV+ adults on suppressive antiretroviral therapy. JAIDS. 2017;74:134–41.

  20. 20.

    Yen Y-F, Chen M, Jen I, Lan YC, Chuang PH, Liu YL, et al. Association of HIV and opportunistic infections with incident stroke: a nationwide population-based cohort study in Taiwan. JAIDS.. 2017;74:117–25.

  21. 21.

    Bruce J. The difficulties of ‘living while girl’. J Virus Erad. 2016;2:177.

  22. 22.

    Seecheran VK, Giddings SL, Seecheran NA. Acute coronary syndromes in patients with HIV. Cor Art Dis.. 2017;28:166.

  23. 23.

    El-Sadr WM, Mayer KH, Maslankowski L, Hoesley C, Justman J, Gai F, et al. Safety and acceptability of cellulose sulfate as a vaginal microbicide in HIV-infected women. AIDS. 2006;20:1109–16.

  24. 24.

    Kearns A, Gordon J, Burdo TH, Qin X. HIV-1–associated atherosclerosis: unraveling the missing link. JACC.. 2017;69:3084–98.

  25. 25.

    McCrary AW, Nduka CU, Stranges S, Bloomfield GS. Features of cardiovascular disease in low-income and middle-income countries in adults and children living with HIV. Curr Opin HIV/AIDS.. 2017;12:579–84.

  26. 26.

    De Francesco MA, Baronio M, Fiorentini S, Signorini C, Bonfanti C, Poiesi C, et al. HIV-1 matrix protein p17 increases the production of proinflammatory cytokines and counteracts IL-4 activity by binding to a cellular receptor. PNAS.. 2002;99:9972–7.

  27. 27.

    Vitale M, Caruso A, De Francesco MA, Rodella L, Bozzo L, Garrafa E, et al. HIV‐1 matrix protein p17 enhances the proliferative activity of natural killer cells and increases their ability to secrete proinflammatory cytokines. B J Haematol. 2003;120:337–43.

  28. 28.

    Marini E, Tiberio L, Caracciolo S, Tosti G, Guzman CA, Schiaffonati L, et al. HIV‐1 matrix protein p17 binds to monocytes and selectively stimulates MCP‐1 secretion: role of transcriptional factor AP‐1. Cell Microbiol. 2008;10:655–66.

  29. 29.

    Giagulli C, Marsico S, Magiera AK, Bruno Rosalinda, Caccuri Francesca, Barone Ines, et al. Opposite effects of HIV-1 p17 variants on PTEN activation and cell growth in B cells. PLoS ONE. 2011;6:e17831.

  30. 30.

    Grogg K, Miller R, Dogan A. HIV infection and lymphoma. J Clin Pathol. 2007;60:1365–72.

  31. 31.

    Carbone A, Gloghini A, Caruso A, De Paoli P, Dolcetti R. The impact of EBV and HIV infection on the microenvironmental niche underlying Hodgkin lymphoma pathogenesis. Int J Cancer. 2017;140:1233–45.

  32. 32.

    Bohlius J, Schmidlin K, Costagliola D, Fätkenheuer G, May M, Caro-Murillo AM, et al. Incidence and risk factors of HIV-related non-Hodgkin’s lymphoma in the era of combination antiretroviral therapy: a European multicohort study. Antivir Ther. 2009;14:1065.

  33. 33.

    Kowalkowski MA, Day RS, Du XL, Chan W, Chiao EY Cumulative HIV viremia and non-AIDS-defining malignancies among a sample of HIV-infected male veterans. JAIDS (1999). 2014;67:204.

  34. 34.

    Shiels MS, Engels EA, Linet MS, Clarke CA, Li J, Hall HI, et al. The epidemic of non–Hodgkin lymphoma in the United States: disentangling the effect of HIV, 1992–2009. Cancer Epidemiol Prev Biomark.. 2013;22:1069–78.

  35. 35.

    Oliver NT, Chiao EY. Malignancies in women with HIV infection. Curr Opin HIV/AIDS.. 2017;12:69.

  36. 36.

    Aserlind A, Maguire K, Duthely L, Wennin Stefan, Potter JoNell. Women living with HIV over age of 65: cervical cancer screening in a unique and growing population. Infect Dis Obstet Gynecol. 2017;2017:2105061.

  37. 37.

    Mthembu NN, Mbita Z, Hull R, Dlamini Zodwa. Abnormalities in alternative splicing of angiogenesisrelated genes and their role in HIV-related cancers. HIV/AIDS.. 2017;9:77.

  38. 38.

    Giagulli C, D’ursi P, He W, Zorzan Simone, Caccuri Francesca, Varney Kristen, et al. A single amino acid substitution confers B-cell clonogenic activity to the HIV-1 matrix protein p17. Sci Rep. 2017;7:6555.

  39. 39.

    Giagulli C, Magiera AK, Bugatti A, Caccuri F, Marsico S, Rusnati M, et al. HIV-1 matrix protein p17 binds to the IL-8 receptor CXCR1 and shows IL-8–like chemokine activity on monocytes through Rho/ROCK activation. Blood. 2012;119:2274–83.

  40. 40.

    Zlokovic BV. Neurovascular mechanisms of Alzheimer’s neurodegeneration. Trends Neurosci. 2005;28:202–8.

  41. 41.

    Grammas P, Martinez J, Sanchez A, Yin X, Riley J, Gay D, et al. A new paradigm for the treatment of Alzheimer’s disease: targeting vascular activation. J Alzheimers Dis. 2014;40:619–30.

  42. 42.

    Talwar P, Silla Y, Grover S, Gupta M, Agarwal R, Kushwaha S, et al. Genomic convergence and network analysis approach to identify candidate genes in Alzheimer’s disease. BMC Genom. 2014;15:199.

  43. 43.

    Hashimoto Y, Niikura T, Chiba T, Tsukamoto E, Kadowaki H, Nishitoh H, et al. The cytoplasmic domain of Alzheimer’s amyloid-β protein precursor causes sustained apoptosis signal-regulating kinase 1/c-Jun NH2- terminal kinase-mediated neurotoxic signal via dimerization. J Pharmacol Exp Ther. 2003;306:889–902.

  44. 44.

    Wang X, Chen Q, Xing D. Focal adhesion kinase activates NF-κB via the ERK1/2 and p38MAPK pathways in amyloid-β 25-35-induced apoptosis in PC12 cells. J Alzheimers Dis. 2012;32:77–94.

  45. 45.

    Epeldegui M, Vendrame E, Martínez-Maza O. HIV-associated immune dysfunction and viral infection: role in the pathogenesis of AIDS-related lymphoma. Immunol Res. 2010;48:72–83.

  46. 46.

    Pepper MS, Tille J-C, Nisato R, Skobe M. Lymphangiogenesis and tumor metastasis. Cell Tissue Res. 2003;314:167–77.

  47. 47.

    Mazzuca P, Marsico S, Schulze K, Mitola S, Pils MC, Giagulli C, et al. Role of autophagy in HIV-1 matrix protein p17-driven lymphangiogenesis. J Virol. 2017;91:e00801–00817.

  48. 48.

    Magi S, Takemoto Y, Kobayashi H, Kasamatsu Masato, Akita Takahiro, Tanaka Ayako, et al. 5‐ Lipoxygenase and cysteinyl leukotriene receptor 1 regulate epidermal growth factor‐induced cell migration through Tiam1 upregulation and Rac1 activation. Cancer Sci. 2014;105:290–6.

  49. 49.

    Wang Y, Qiu J, Luo S, Xie Xiang, Zheng Yiming, Zhang Kang, et al. High shear stress induces atherosclerotic vulnerable plaque formation through angiogenesis. Regen Biomat.. 2016;3:257–67.

  50. 50.

    Kayima J, Nyakoojo W, Nakanjako D, Costa MarcoA, Longenecker ChristopherT, Simon DanielI. Acute spontaneous coronary artery thrombosis as initial presentation of HIV infection in a young man. Case Rep Cardiol. 2015;2015:342348.

  51. 51.

    Kulkarni M, Bowman E, Gabriel J, Amburgy T, Mayne E, Zidar DA, et al. Altered monocyte and endothelial cell adhesion molecule expression is linked to vascular inflammation in human immunodeficiency virus infection. Open Forum Infect Dis. 2016;3:ofw224.

  52. 52.

    Renga B, Francisci D, D’Amore C, Schiaroli Elisabetta, Mencarelli Andrea, Cipriani Sabrina, et al. The HIV matrix protein p17 subverts nuclear receptors expression and induces a STAT1-dependent proinflammatory phenotype in monocytes. PLoS ONE. 2012;7:e35924.

Download references

Author information


  1. School of Healthcare Science, John Dalton Building, Manchester Metropolitan University, Chester Street, Manchester, M1 5GD, UK

    • Donghui Liu
    • , Yasmin Zeinolabediny
    • , Glenn Ferris
    • , Wen-Hui Fang
    • , Ria Weston
    • , Jerzy Krupinski
    • , Baoqiang Guo
    •  & Mark Slevin
  2. University of Medicine and Pharmacy, Targu Mures, Romania

    • Donghui Liu
    • , Yasmin Zeinolabediny
    •  & Mark Slevin
  3. Department of Molecular and Translational Medicine, Section of Microbiology, University of Brescia Medical School, Brescia, Italy

    • Francesca Caccuri
    •  & Arnaldo Caruso
  4. Hospital Universitari Mútua de Terrassa, Department of Neurology, Terrassa, Barcelona, Spain

    • Jerzy Krupinski
  5. Department of Molecular Biochemistry and Pharmacology, IRCCS Istituto di Ricerche Farmacologiche “Mario Negri”, Milan, Italy

    • Laura Colombo
    •  & Mario Salmona
  6. Instituto De Investigaciones Biomedicas De Barcelona, CSIC, Barcelona, Spain

    • Ruben Corpas
    • , Sara Sarroca
    •  & Coral Sanfeliu
  7. Weifang Medical University, Weifang, China

    • Xianwei Zeng
    •  & Mark Slevin


  1. Search for Donghui Liu in:

  2. Search for Yasmin Zeinolabediny in:

  3. Search for Francesca Caccuri in:

  4. Search for Glenn Ferris in:

  5. Search for Wen-Hui Fang in:

  6. Search for Ria Weston in:

  7. Search for Jerzy Krupinski in:

  8. Search for Laura Colombo in:

  9. Search for Mario Salmona in:

  10. Search for Ruben Corpas in:

  11. Search for Sara Sarroca in:

  12. Search for Coral Sanfeliu in:

  13. Search for Arnaldo Caruso in:

  14. Search for Baoqiang Guo in:

  15. Search for Xianwei Zeng in:

  16. Search for Mark Slevin in:

Conflict of interest

The authors declare that they have no conflict of interest.

Corresponding author

Correspondence to Mark Slevin.

Electronic supplementary material

About this article

Publication history